1 Guidance

1 Guidance

1.1 Bevacizumab in combination with 5-fluorouracil plus folinic acid, with or without irinotecan, is not recommended for the first-line treatment of metastatic colorectal cancer.

1.2 This recommendation has been updated and replaced by NICE technology appraisal guidance 242.

1.3 People currently receiving bevacizumab or cetuximab should have the option to continue therapy until they and their consultants consider it appropriate to stop.